OKYO Pharma CSO buys 3,363 shares at $1.49

OKYO Pharma Limited reported that its Chief Scientific Officer, Raj Patil, PhD, purchased 3,363 ordinary shares on Nasdaq at $1.49 per share, increasing his total holding to 20,030 ordinary shares.

Rhea-AI Filing Summary

OKYO Pharma Limited reported that its Chief Scientific Officer, Raj Patil, PhD, purchased 3,363 ordinary shares on Nasdaq at $1.49 per share, increasing his total holding to 20,030 ordinary shares.

The company is a clinical-stage biopharmaceutical business focused on neuropathic corneal pain and anterior segment eye diseases and plans a global Phase 3 pivotal trial of urcosimod in the second half of the year, enrolling approximately 111 patients. This disclosure is incorporated by reference into its Form F-3 registration statement (Reg. No. 333-293145).

Filing Explained

The July 28 Form 6-K furnishes the share-purchase announcement as Exhibit 99.1; the exhibit is not deemed filed under Section 18, while the report is incorporated by reference into the company’s Form F-3 registration statement.

Key Figures

Shares purchased by CSO: 3,363 ordinary shares Purchase price per share: $1.49 per share Total CSO holdings after purchase: 20,030 ordinary shares +2 more

5 metrics

Shares purchased by CSO 3,363 ordinary shares Ordinary shares bought on Nasdaq by Chief Scientific Officer Raj Patil

Purchase price per share $1.49 per share Price paid on Nasdaq for the 3,363 ordinary shares

Total CSO holdings after purchase 20,030 ordinary shares Raj Patil's total holding of company ordinary shares after the transaction

Planned Phase 3 trial enrollment approximately 111 patients Planned enrollment for global Phase 3 pivotal trial of urcosimod for NCP

Form F-3 registration number 333-293145 Registration statement into which this disclosure is incorporated by reference

Key Terms

neuropathic corneal pain (NCP), anterior segment eye diseases, Phase 3 pivotal clinical trial, single-dose regimen, +2 more

6 terms

neuropathic corneal pain (NCP) medical

"developing investigational therapies for the treatment of neuropathic corneal pain (NCP)"

Neuropathic corneal pain is chronic eye pain caused by damage or abnormal signaling in the nerves of the cornea, producing burning, stinging, or painful sensitivity often without visible surface injury. It matters to investors because it creates demand for specialized diagnostics and long‑term treatments distinct from standard eye drops—think of it like phantom limb pain for the eye—making it a potential market for new therapies and medical devices.

anterior segment eye diseases medical

"developing innovative therapies for the treatment of NCP and anterior segment eye diseases"

Diseases of the anterior segment of the eye are medical conditions that affect the front part of the eye—including the cornea, iris, lens, and the front chamber—similar to damage or fogging on a car’s windshield that interferes with vision. They matter to investors because this category drives demand for drugs, surgical devices, diagnostic tools, and clinical trials; prevalence, regulatory approvals, and reimbursement decisions can directly affect companies’ revenues and valuations.

Phase 3 pivotal clinical trial medical

"plans to initiate a global Phase 3 pivotal clinical trial in the second half"

A phase 3 pivotal clinical trial is the late-stage, large-scale human study designed to confirm a medical treatment’s safety and effectiveness and provide the main evidence regulators use to decide on approval. For investors it’s a make-or-break test: a successful result is like a final dress rehearsal that clears the way for product launch and future sales, while failure can halt development and erase expected value.

single-dose regimen medical

"to evaluate a single-dose regimen of urcosimod for the treatment of NCP"

A single-dose regimen is a treatment plan in which a medication or vaccine is administered just once to produce the intended protective or therapeutic effect, rather than through multiple injections or pills over days or weeks. It matters to investors because single-dose products can simplify distribution, lower treatment costs, improve patient adherence, and change market demand and regulatory review timelines—much like a one-time purchase versus an ongoing subscription.

urcosimod medical

"evaluate a single-dose regimen of urcosimod for the treatment of NCP"

clinical-stage biopharmaceutical company medical

"OKYO Pharma Limited is a clinical-stage biopharmaceutical company developing innovative therapies"

A clinical-stage biopharmaceutical company develops drugs or medical therapies that are being tested in people in formal clinical trials but do not yet have any approved, marketed products. For investors, these firms behave like prototype makers: their value depends heavily on trial results and regulatory decisions, so they can swing widely on a single study, consume cash while testing, and offer either large upside if trials succeed or big downside if they fail.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What share purchase did OKYO (OKYO) disclose involving its Chief Scientific Officer?

OKYO Pharma disclosed that Chief Scientific Officer Raj Patil bought 3,363 ordinary shares on Nasdaq at $1.49 per share, increasing his total holding to 20,030 ordinary shares. This transaction raised his personal equity stake in the company.

What is OKYO Pharma (OKYO) focused on developing?

OKYO Pharma is a clinical-stage biopharmaceutical company developing therapies for neuropathic corneal pain (NCP) and anterior segment eye diseases. Its ordinary shares are listed for trading on the Nasdaq Capital Market under the symbol OKYO.

What Phase 3 trial has OKYO (OKYO) said it plans to start?

OKYO plans a global Phase 3 pivotal clinical trial in the second half of the year, enrolling approximately 111 patients to evaluate a single-dose regimen of urcosimod for the treatment of neuropathic corneal pain (NCP).

How many OKYO (OKYO) shares will Raj Patil own after his latest purchase?

After buying 3,363 ordinary shares at $1.49 per share, Chief Scientific Officer Raj Patil’s total holding increases to 20,030 ordinary shares of OKYO Pharma, according to the company’s July 2026 disclosure.

How is this disclosure by OKYO (OKYO) linked to its registration statement?

The company states that this report is incorporated by reference into its Form F-3 registration statement, identified as Registration No. 333-293145. This links the disclosed information directly to that existing securities registration.

On which market did the OKYO (OKYO) insider share purchase occur?

The company reports that Raj Patil purchased 3,363 ordinary shares of OKYO Pharma on Nasdaq at $1.49 per share. Separately, it notes that its ordinary shares are listed on the Nasdaq Capital Market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/28/2026 - 07:00 AM Accepted by SEC EDGAR 07/28/2026 - 07:00 AM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

July 2026

Commission File Number: 001-41386

OKYO Pharma LTD

(Exact Name of Registrant as Specified in Its Charter)

9^th Floor

107 Cheapside

London

EC2V 6DN

(Address of registrant’s principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

On July 28, 2026, OKYO Pharma LTD (the “Company”) issued this 6K announcing that Raj Patil, PhD, Chief Scientific Officer of OKYO Pharma has increased his holdings with the purchase of 3,363 of the Company’s ordinary shares on NASDAQ at $1.49 per share, bringing his total holding to 20,030 ordinary shares.

The Announcement is furnished herewith as Exhibit 99.1 to this Report on Form 6-K. The information in the attached Exhibits 99.1 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that Section, This report on Form 6-K is hereby incorporated by reference into the Company’s Registration Statement on Form F-3 (Reg. No. 333-293145)

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	OKYO Pharma LTD
Date: July 28, 2026	By:	/s/ Keeren Shah
	Name:	Keeren Shah
	Title:	Chief Financial Officer

3

EXHIBIT INDEX

Exhibit No.		Description
99.1		News Announcement, dated July 28, 2026

4

Exhibit 99.1

OKYO Pharma Announces Purchase of Shares by Chief Scientific Officer

London and New York, NY, July 28, 2026. OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced that Raj Patil, PhD, Chief Scientific Officer of OKYO Pharma has increased his holdings with the purchase of 3,363 of the Company’s ordinary shares on NASDAQ at $1.49 per share, bringing his total holding to 20,030 ordinary shares.

About OKYO Pharma

OKYO Pharma Limited (Nasdaq: OKYO) is a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, with ordinary shares listed for trading on the Nasdaq Capital Market. OKYO plans to initiate a global Phase 3 pivotal clinical trial in the second half of this year, enrolling approximately 111 patients to evaluate a single-dose regimen of urcosimod for the treatment of NCP.

For further information, please visit www.okyopharma.com.

For further inquiries:

OKYO Pharma Ltd

Paul Spencer

Business Development and Investor Relations

+44 (0) 207 495 2379

Email: info@okyopharma.com

Filing Exhibits & Attachments

2 documents

Press Releases

• EX-99.1 EX-99.1 6.0 KB
• EX-99 GRAPHIC 25.8 KB